X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1042) 1042
Publication (86) 86
Book Review (13) 13
Book Chapter (6) 6
Magazine Article (2) 2
Newsletter (2) 2
Conference Proceeding (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (810) 810
flucytosine - therapeutic use (463) 463
male (391) 391
flucytosine - administration & dosage (386) 386
female (335) 335
amphotericin b - therapeutic use (293) 293
animals (287) 287
amphotericin b - administration & dosage (279) 279
flucytosine (258) 258
antifungal agents - therapeutic use (253) 253
drug therapy, combination (240) 240
index medicus (240) 240
adult (234) 234
antifungal agents - administration & dosage (197) 197
mice (187) 187
fluconazole (178) 178
candidiasis - drug therapy (177) 177
middle aged (174) 174
flucytosine - pharmacology (160) 160
cytosine deaminase (156) 156
amphotericin b (153) 153
infectious diseases (151) 151
cryptococcosis - drug therapy (138) 138
mycoses - drug therapy (125) 125
oncology (125) 125
amphotericin-b (118) 118
cytosine deaminase - genetics (117) 117
5-fluorocytosine (114) 114
aged (112) 112
microbiology (112) 112
pharmacology & pharmacy (111) 111
meningitis (106) 106
therapy (105) 105
health aspects (101) 101
gene therapy (94) 94
fluconazole - therapeutic use (93) 93
cryptococcal meningitis (91) 91
medicine, research & experimental (89) 89
cytosine - analogs & derivatives (87) 87
genetic therapy - methods (86) 86
meningitis, cryptococcal - drug therapy (86) 86
fluconazole - administration & dosage (85) 85
cancer (84) 84
antifungal agents - pharmacology (82) 82
biotechnology & applied microbiology (81) 81
care and treatment (80) 80
flucytosine - metabolism (80) 80
antifungal agents (78) 78
administration, oral (76) 76
cell line, tumor (76) 76
in-vivo (75) 75
genetics & heredity (74) 74
aids (72) 72
amphotericin b - pharmacology (72) 72
cytosine deaminase - metabolism (72) 72
flucytosine - adverse effects (72) 72
adolescent (71) 71
microbial sensitivity tests (70) 70
infections (69) 69
treatment outcome (68) 68
5-fluorouracil (67) 67
amphotericin b - adverse effects (67) 67
flucytosine - pharmacokinetics (65) 65
genetic therapy (64) 64
research (64) 64
mice, nude (62) 62
itraconazole (61) 61
aspergillosis - drug therapy (60) 60
nucleoside deaminases - genetics (58) 58
drug therapy (57) 57
antifungal agents - adverse effects (56) 56
medicine, general & internal (55) 55
rats (55) 55
dosage and administration (53) 53
infant, newborn (53) 53
combined modality therapy (51) 51
cryptococcosis (51) 51
pharmacokinetics (51) 51
meningitis - drug therapy (50) 50
tumor cells, cultured (50) 50
mortality (49) 49
child (48) 48
time factors (48) 48
chemotherapy (47) 47
immunology (47) 47
prodrugs - therapeutic use (47) 47
infection (45) 45
mycology (45) 45
voriconazole (45) 45
cryptococcus neoformans - isolation & purification (43) 43
expression (43) 43
fluorouracil - metabolism (43) 43
risk factors (43) 43
aids-related opportunistic infections - drug therapy (42) 42
disease models, animal (42) 42
genetic vectors (42) 42
mice, inbred balb c (42) 42
candida - drug effects (41) 41
tumors (41) 41
candidiasis (40) 40
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (950) 950
French (22) 22
German (22) 22
Japanese (21) 21
Spanish (13) 13
Portuguese (6) 6
Chinese (5) 5
Italian (5) 5
Polish (2) 2
Danish (1) 1
Dutch (1) 1
Hungarian (1) 1
Norwegian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 03/2018, Volume 378, Issue 11, pp. 1004 - 1017
Journal Article
AIDS, ISSN 0269-9370, 06/2012, Volume 26, Issue 9, pp. 1105 - 1113
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 2/2010, Volume 50, Issue 3, pp. 338 - 344
Background. Cryptococcal meningitis is a major cause of human immunodeficiency virus (HIV)–associated morbidity and mortality in Africa. Improved oral... 
Viral meningitis | Cryptococcal meningitis | Infectious diseases | HIV | Mortality | AIDS | Infections | Cerebrospinal fluid | ARTICLES AND COMMENTARIES | Dosage | Neutropenia | INFECTIOUS DISEASES | FUNGICIDAL ACTIVITY | SUB-SAHARAN AFRICA | ADULTS | MICROBIOLOGY | AMPHOTERICIN-B | IMMUNOLOGY | HUMAN-IMMUNODEFICIENCY-VIRUS | BACTERIAL-MENINGITIS | ACTIVE ANTIRETROVIRAL THERAPY | DISEASE | INFECTION | Antifungal Agents - adverse effects | Meningitis, Cryptococcal - drug therapy | Humans | Middle Aged | Fluconazole - administration & dosage | Fluconazole - adverse effects | Male | Meningitis, Cryptococcal - microbiology | Fluconazole - therapeutic use | Antifungal Agents - therapeutic use | Meningitis, Cryptococcal - mortality | Young Adult | Malawi | AIDS-Related Opportunistic Infections - mortality | Adult | Female | Drug Therapy, Combination | Flucytosine - administration & dosage | Administration, Oral | AIDS-Related Opportunistic Infections - drug therapy | Treatment Outcome | AIDS-Related Opportunistic Infections - microbiology | Flucytosine - adverse effects | Flucytosine - therapeutic use | Cryptococcus - isolation & purification | HIV Infections - complications | Aged | Cerebrospinal Fluid - microbiology | Antifungal Agents - administration & dosage | Care and treatment | Fluconazole | Patient outcomes | Flucytosine | Dosage and administration | Research | Drug therapy, Combination
Journal Article
Biomaterials, ISSN 0142-9612, 2015, Volume 80, pp. 57 - 67
Abstract Metastatic prostate cancer causes significant morbidity and mortality and there is a critical unmet need for effective treatments. We have developed a... 
Advanced Basic Science | Dentistry | Theranostic imaging | PSMA | TRAIL | Gene therapy | Prostate cancer | Prodrug enzyme therapy | THERAPEUTICS | APOPTOSIS | CELLS | MATERIALS SCIENCE, BIOMATERIALS | LIGAND TRAIL | ENGINEERING, BIOMEDICAL | MEMBRANE ANTIGEN PSMA | DELIVERY | NANOPARTICLES | HEPATOCELLULAR-CARCINOMA | IN-VIVO | INHIBITORS | Prodrugs - administration & dosage | Enzyme Therapy | Genetic Therapy | Prostatic Neoplasms - metabolism | Theranostic Nanomedicine | Humans | DNA - therapeutic use | Male | Antimetabolites - therapeutic use | Prodrugs - metabolism | Prostate - metabolism | Drug Delivery Systems | Prostatic Neoplasms - therapy | Prostate - pathology | Glutamate Carboxypeptidase II - metabolism | Cytosine Deaminase - metabolism | Cytosine Deaminase - therapeutic use | Cytosine Deaminase - administration & dosage | Plasmids - genetics | Antigens, Surface - metabolism | Prostate - drug effects | Antimetabolites - metabolism | Prostatic Neoplasms - pathology | Flucytosine - administration & dosage | DNA - administration & dosage | Models, Molecular | Flucytosine - metabolism | Plasmids - therapeutic use | Antimetabolites - administration & dosage | DNA - genetics | Animals | Flucytosine - therapeutic use | Cell Line, Tumor | Bacteria - enzymology | Mice | Prodrugs - therapeutic use | TNF-Related Apoptosis-Inducing Ligand - genetics | Plasmids - administration & dosage | Enzymes | Care and treatment | Genes | Mortality | Genetic research | Genetic aspects | Health aspects | Fluorouracil | Cancer | Antigens | Medical colleges | Metastasis | Drugs | Therapy | Bacteria | Nanostructure | Prostate | Chemical compounds | Tumors | gene therapy | prostate cancer | prodrug enzyme therapy | theranostic imaging
Journal Article
Human Gene Therapy, ISSN 1043-0342, 02/2015, Volume 26, Issue 2, pp. 82 - 93
Toca 511 (vocimagene amiretrorepvec), a nonlytic, amphotropic retroviral replicating vector (RRV), encodes and delivers a functionally optimized yeast cytosine... 
Research Articles | MEDICINE, RESEARCH & EXPERIMENTAL | APOPTOSIS | LONG-TERM EXPRESSION | MURINE LEUKEMIA-VIRUS | BRAIN-TUMORS | 5-FLUOROURACIL | IN-VITRO | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | GENETICS & HEREDITY | KUPFFER CELLS | GENE-THERAPY | MICE | RECURRENT GLIOBLASTOMA-MULTIFORME | Antibodies, Neutralizing - analysis | Injections, Intravenous | Genetic Vectors - administration & dosage | Humans | Brain Neoplasms - pathology | Recombinant Proteins - pharmacokinetics | Green Fluorescent Proteins - genetics | Glioma - genetics | Tissue Distribution | Cytosine Deaminase - metabolism | Retroviridae - genetics | Cytosine Deaminase - pharmacokinetics | Glioma - pathology | Glioma - therapy | Brain Neoplasms - mortality | Drug Evaluation, Preclinical | Cytosine Deaminase - genetics | Genes, Reporter | Antimetabolites - pharmacology | Disease Models, Animal | Recombinant Proteins - metabolism | Green Fluorescent Proteins - metabolism | Gene Expression | Glioma - mortality | Genetic Vectors - chemistry | Brain Neoplasms - genetics | Fungal Proteins - pharmacokinetics | Retroviridae - immunology | Clinical Trials as Topic | Recombinant Proteins - genetics | Fungal Proteins - genetics | Animals | Mice, Nude | Brain Neoplasms - therapy | Survival Analysis | Mice | Flucytosine - pharmacology | Genetic Vectors - pharmacokinetics | Fungal Proteins - metabolism | Genetic Therapy - methods
Journal Article
Mycopathologia, ISSN 0301-486X, 09/2011, Volume 172, Issue 3, pp. 227 - 232
Rituximab-related late-onset neutropenia (R-LON) is an adverse event associated with rituximab. A 65-year-old woman presented with diffuse large B-cell... 
Rituximab | Malignant lymphoma | Late onset | Cryptococcosis | Neutropenia | METAANALYSIS | MENINGOENCEPHALITIS | TRANSPLANTATION | B-CELL LYMPHOMA | INFECTIOUS COMPLICATIONS | NEOFORMANS | THERAPY | DISEASE | MALIGNANCIES | CENTRAL-NERVOUS-SYSTEM | MYCOLOGY | Prednisolone - adverse effects | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prednisolone - administration & dosage | Humans | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Fluconazole - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Cryptococcosis - drug therapy | Cyclophosphamide - adverse effects | Lymphoma, Non-Hodgkin - complications | Amphotericin B - administration & dosage | Vincristine - administration & dosage | Female | Neutropenia - chemically induced | Doxorubicin - administration & dosage | Lymphoma, Non-Hodgkin - drug therapy | Cryptococcus neoformans - isolation & purification | Flucytosine - administration & dosage | Immunologic Factors - administration & dosage | Treatment Outcome | Cryptococcosis - diagnosis | Vincristine - adverse effects | Aged | Immunologic Factors - adverse effects | Antibodies, Monoclonal, Murine-Derived - adverse effects | Antifungal Agents - administration & dosage | Doxorubicin - adverse effects | Complications and side effects | Chemotherapy | Cryptococcal infections | Fluconazole | Meningitis | Lymphomas | Cancer
Journal Article
The Lancet, ISSN 0140-6736, 05/2004, Volume 363, Issue 9423, pp. 1764 - 1767
It frequently takes more than 2 weeks for drug treatments for cryptococcal meningitis to sterilise cerebrospinal fluid (CSF). In-vitro and animal studies lend... 
ACQUIRED-IMMUNODEFICIENCY-SYNDROME | THAILAND | MEDICINE, GENERAL & INTERNAL | AIDS | AMPHOTERICIN-B | FLUCONAZOLE | Cryptococcus neoformans - isolation & purification | Flucytosine - administration & dosage | Meningitis, Cryptococcal - drug therapy | Meningitis, Cryptococcal - cerebrospinal fluid | Humans | AIDS-Related Opportunistic Infections - drug therapy | Fluconazole - administration & dosage | AIDS-Related Opportunistic Infections - diagnosis | Male | Colony Count, Microbial | Cerebrospinal Fluid - cytology | Meningitis, Cryptococcal - diagnosis | Meningitis, Cryptococcal - microbiology | Antigens, Fungal - cerebrospinal fluid | Cerebrospinal Fluid Pressure | AIDS-Related Opportunistic Infections - microbiology | AIDS-Related Opportunistic Infections - cerebrospinal fluid | Amphotericin B - administration & dosage | Adult | Female | Cerebrospinal Fluid - microbiology | Drug Therapy, Combination | Antifungal Agents - administration & dosage | Cryptococcal meningitis | Complications | Antifungal agents | Dosage and administration | Drug therapy | HIV infection | Risk factors | Fungi | Meningitis | Medical treatment | Human immunodeficiency virus--HIV | Therapy | Fungicides | Fluconazole | Laboratories | Mortality | Cryptococcosis | Cultures | Cerebrospinal fluid | Multivariate analysis | Patients | Clinical outcomes | Studies | Randomization | Tuberculosis | Fungicidal activity | Amphotericin B | Acquired immune deficiency syndrome--AIDS | Flucytosine
Journal Article
AIDS, ISSN 0269-9370, 07/2012, Volume 26, Issue 11, pp. 1363 - 1370
Journal Article
Journal de Mycologie Médicale, ISSN 1156-5233, 03/2015, Volume 25, Issue 1, pp. 63 - 70
Journal Article
American Journal of Medicine, The, ISSN 0002-9343, 2012, Volume 125, Issue 1, pp. S25 - S38
Abstract Effective management of invasive fungal infections (IFIs) depends on early individualized therapy that optimizes efficacy and safety. Considering the... 
Internal Medicine | Therapeutic drug monitoring | Echinocandins | Mucormycosis | Amphotericin B | Triazoles | Hepatotoxicity | ORBITAL-CEREBRAL MUCORMYCOSIS | RECEIVING VORICONAZOLE PROPHYLAXIS | IN-VITRO SUSCEPTIBILITIES | BREAKTHROUGH FUNGAL-INFECTIONS | PREEMPTIVE ANTIFUNGAL THERAPY | CLINICAL-PRACTICE GUIDELINES | CELL TRANSPLANT RECIPIENTS | MEDICINE, GENERAL & INTERNAL | HEALTHY MALE-VOLUNTEERS | INFECTIOUS-DISEASES-SOCIETY | LIPOSOMAL-AMPHOTERICIN-B | Triazoles - administration & dosage | Triazoles - adverse effects | Antifungal Agents - adverse effects | Humans | Middle Aged | Mycoses - microbiology | Male | Alanine Transaminase - blood | Antineoplastic Agents - administration & dosage | Echinocandins - administration & dosage | Liver - drug effects | Antineoplastic Agents - adverse effects | Antifungal Agents - pharmacokinetics | Mycoses - metabolism | Adult | Female | Mucormycosis - surgery | Mucormycosis - drug therapy | Alkaline Phosphatase - blood | Myelodysplastic Syndromes - drug therapy | Aspergillosis - drug therapy | Flucytosine - administration & dosage | Liver - metabolism | Risk Factors | Leukemia - drug therapy | Mycoses - surgery | Pneumonia - microbiology | Biomarkers - blood | Bilirubin - blood | Flucytosine - adverse effects | Echinocandins - adverse effects | Pneumonia - drug therapy | Aspartate Aminotransferases - blood | Liver Function Tests - standards | Opportunistic Infections - drug therapy | Mycoses - drug therapy | Immunocompromised Host | Drug Monitoring | Antifungal Agents - administration & dosage | Care and treatment | Mycoses | Diagnosis | Research | Health aspects | Risk factors | Drugs | flucytosine | Pharmacodynamics | Risk groups | Mortality | Antifungal agents | Molds | triazoles | Epidemiology | Radicals | Infection | Lipophilic | hepatotoxicity | Voriconazole | Pharmacokinetics | Posaconazole | Itraconazole
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 7/2008, Volume 47, Issue 1, pp. 123 - 130
Journal Article